title: Waterhouse-Friderichsen syndrome due to Neisseria meningitidis infection in a young adult with thrombotic microangiopathy and eculizumab treatment: case report and review of management.
authors.affiliation: Department of Internal Medicine, Clinical Division of Nephrology, Medical University Graz, Graz, Austria.
authors.forename: Claudia
authors.initials: C
authors.lastname: Friedl
authors.affiliation: Department of Internal Medicine, Intensive Care Unit, Medical University of Graz, Auenbruggerplatz 15, A-8036, Graz, Austria.
authors.forename: Gerald
authors.initials: G
authors.lastname: Hackl
authors.affiliation: Department of Internal Medicine, Clinical Division of Nephrology, Medical University Graz, Graz, Austria.|Department of Internal Medicine, Intensive Care Unit, Medical University of Graz, Auenbruggerplatz 15, A-8036, Graz, Austria.
authors.forename: Gernot
authors.initials: G
authors.lastname: Schilcher
authors.affiliation: Department of Internal Medicine, Clinical Division of Nephrology, Medical University Graz, Graz, Austria.
authors.forename: Alexander R
authors.initials: AR
authors.lastname: Rosenkranz
authors.affiliation: Department of Internal Medicine, Clinical Division of Nephrology, Medical University Graz, Graz, Austria.
authors.forename: Kathrin
authors.initials: K
authors.lastname: Eller
authors.affiliation: Department of Internal Medicine, Intensive Care Unit, Medical University of Graz, Auenbruggerplatz 15, A-8036, Graz, Austria. philipp.eller@medunigraz.at.
authors.forename: Philipp
authors.initials: P
authors.lastname: Eller
mesh_terms: D058186:Acute Kidney Injury / Q000150:complications / Q000209:etiology / Q000276:immunology / Q000628:therapy; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004211:Disseminated Intravascular Coagulation / Q000150:complications / Q000209:etiology / Q000628:therapy; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007362:Intensive Care Units; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D008297:Male; D008589:Meningococcal Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology*; D038582:Neisseria meningitidis, Serogroup W-135 / Q000187:drug effects / Q000276:immunology* / Q000302:isolation & purification; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology*; D045169:Severe Acute Respiratory Syndrome / Q000150:complications / Q000209:etiology / Q000276:immunology / Q000628:therapy; D012772:Shock, Septic / Q000150:complications / Q000209:etiology / Q000276:immunology / Q000628:therapy; D057049:Thrombotic Microangiopathies / Q000150:complications* / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D016896:Treatment Outcome; D014884:Waterhouse-Friderichsen Syndrome / Q000209:etiology* / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D002939:Ciprofloxacin; C481642:eculizumab